NCT00928694View on ClinicalTrials.gov

Fenofibrate Bioequivalence Study (0767-031)

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

April 30, 2003

Study Completion Date

April 30, 2004

Conditions
Dyslipidemia
Interventions
DRUG

fenofibrate (U.S. formulation)

Single dose of 160 mg fenofibrate U.S. formulation (Tricor®) in one of two treatment periods.

DRUG

fenofibrate (UK formulation)

Single dose of 160 mg fenofibrate UK formulation (Supralip®) in one of two treatment periods.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00928694 - Fenofibrate Bioequivalence Study (0767-031) | Biotech Hunter | Biotech Hunter